X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The new company will be headquartered will acquire Cellex’s subsidiary GEMoaB GmbH with established offices and labs in Dresden, Germany. GEMoaB is developing a switchable universal platform UniCAR-T-CD123 to improve the therapeutic window of CAR T-cell therapies.
Lead Product(s): UniCAR-T-CD123
Therapeutic Area: Oncology Product Name: UniCAR-T-CD123
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 22, 2021
Details:
GEMoaB has apheresed the first patient in a Phase IA study with UniCAR-T-PSMA, the lead solid tumor product candidate from its proprietary UniCAR cellular immunotherapy platform.
Lead Product(s): UniCAR-T-PSMA
Therapeutic Area: Oncology Product Name: UniCAR-T-PSMA
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
The companies will conduct joint research to combine GEMoaB’s proprietary RevCAR technology platform with Intellia’s proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies to treat cancers and inflammatory diseases.
Lead Product(s): RevCAR-T 1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Intellia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 20, 2020
Details:
The AACR poster presentations highlight GEMoaB's rapidly switchable universal CAR-T platform, UniCAR. The UniCAR platform promises an improved therapeutic window and increased efficacy and safety over conventional CAR-T therapies in hematological malignancies and solid tumors.
Lead Product(s): UniCAR-T-CD123
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Apheresed the first patient in a Phase IA study with UniCAR-T-CD123, the lead product candidate from its proprietary UniCAR cellular immunotherapy platform.
Lead Product(s): UniCAR-T-CD123
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
